This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Keith D. Herzog, MD; Sarah S. Long, MD; Mary McGuigan; Margaret C. Fisher, MD; Adamadia Deforest, PhD

Am J Dis Child. 1990;144(9):1001-1004.

Abstract
• During the 1987 through 1988 seasonal peak of respiratory syncytial virus (RSV), 177 courses of ribavirin were administered at St Christopher's Hospital for Children, a tertiary care medical center in Philadelphia, Pa. Charts were reviewed on 100 treated patients with proved or suspected RSV disease to determine adherence to American Academy of Pediatrics treatment guidelines. Ninety-four percent fulfilled criteria for the risk of significant morbidity: cardiac, pulmonary, or immunodeficiency conditions (38%); an age of 6 weeks or younger (35%); or severe illness (21%). Severe illness was defined as hypoxemia, hypercapnia, or marked tachypnea. Of those treated because of underlying conditions, 71% had RSV documented, as did 71% of patients aged 6 weeks or younger and 81% of patients with severe disease. A study of 80 consecutive patients who were hospitalized with illness compatible with RSV infection revealed that 56% of patients were treated with ribavirin. Adherence to guidelines led to ribavirin use in half of the hospitalized patients with suspected RSV infection. The majority of these patients received therapy because of underlying conditions or very young age.

(AJDC. 1990;144:1001-1004)

Author Affiliations
From the Section of Infectious Diseases (Drs Herzog, Long, and Fisher), Medical Records/Quality Assurance (Ms McGuigan), and Department of Laboratory Medicine (Dr Deforest), St Christopher's Hospital for Children, Temple University School of Medicine, Philadelphia, Pa.

Footnotes
Accepted for publication March 5, 1990.

Presented in part at the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, Calif, October 25, 1988.

Reprint requests to Section of Infectious Diseases, St Christopher's Hospital for Children, Erie Ave at Front St, Philadelphia, PA 19134-1095 (Dr Long).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adverse Effects of Ribavirin and Outcome in Severe Acute Respiratory Syndrome: Experience in Two Medical Centers
Chiou et al.
Chest 2005;128:263-272.
ABSTRACT | FULL TEXT